· updated
TB-500: What the Evidence Actually Shows in 2026
TB-500 is the name commonly used for a synthetic fragment related to thymosin beta-4 (Tβ4), a naturally occurring protein involved in cell movement and tissue repair. It shows up constantly in recovery and sports-injury discussions, often alongside BPC-157. The evidence picture is more nuanced than either the hype or the dismissal suggests: real human trial data exists for thymosin beta-4 — just not for the specific product, route, and use case most people are actually discussing.
What it is
Thymosin beta-4 is a small, naturally occurring protein that plays a role in actin regulation — the cellular machinery involved in cell migration and wound healing. TB-500 is typically described as a shorter, synthetic fragment intended to mimic some of Tβ4’s activity. It’s important to note this distinction: the pharmaceutical-grade Tβ4 studied in the trials below is not the same manufactured product as the “TB-500” sold by peptide vendors, even when the marketing implies otherwise.
What the evidence shows — and where the gaps are
- Human trials exist — for specific formulations and conditions. Thymosin beta-4-based eye drops have been tested in placebo-controlled human trials for dry eye disease and neurotrophic keratitis, with benefit shown on objective clinical endpoints. Separately, injectable Tβ4 formulations reached Phase II human trials for chronic and acute skin wound healing, with some early-phase work in venous stasis ulcers.
- No human trial exists for the injectable, systemic use most commonly discussed — i.e., for tendon, ligament, or muscle-strain recovery. No completed Phase II or Phase III randomized controlled trial has tested systemic injectable Tβ4 (or TB-500 specifically) for musculoskeletal injury in humans.
- The animal evidence is broader than the human evidence. Across independent labs, animal models of cardiac injury, corneal injury, dermal wounds, muscle damage, and tendon injury show consistent benefit from Tβ4 administration — faster wound closure, better functional recovery, less scarring. That’s a meaningfully larger and more consistent preclinical base than BPC-157’s, but it still hasn’t been tested in the specific way it’s being discussed for sports and recovery use.
- The product-identity gap matters. Because “TB-500” as sold to consumers is investigational and not the same regulated pharmaceutical product used in the dry-eye and wound-healing trials, none of that trial data can be assumed to apply to it directly — different manufacturing, purity, and formulation all affect safety and activity.
- Regulators have also flagged sport-specific concerns: TB-500 carries WADA-prohibited status for use in competitive athletics, separate from any FDA compounding determination.
Current regulatory status
TB-500 is not an FDA-approved drug. FDA’s Pharmacy Compounding Advisory Committee reviewed TB-500-related bulk drug substances (alongside BPC-157, KPV, and MOTS-c) on July 23, 2026 as part of its evaluation for the 503A Bulks List — the list that would clearly authorize pharmacy compounding. FDA’s own pre-meeting briefing materials reportedly did not support adding it, citing limited characterization and its WADA-prohibited status among the concerns. The committee still voted 8-6 (1 abstention) to recommend it; that vote is advisory and FDA rulemaking is pending. For the current, up-to-date status, see our live legal status tracker, and for the regulatory backstory see the July 2026 PCAC review, explained.
What people discuss with providers
Conversations with licensed providers about TB-500 typically focus on the distinction between the regulated Tβ4 trial data and the unregulated product sold under the TB-500 name, what that gap means for safety and sourcing, and what a provider’s evidence threshold is before considering anything off-label. This is general education, not a recommendation, and it isn’t a substitute for an individualized medical evaluation.